$GILD

The National Plan for Epilepsy Act (S494) establishes a national strategy for epilepsy research and care. This bill directs federal agencies to coordinate efforts, potentially increasing funding for research and treatment development, benefiting pharmaceutical and biotechnology companies focused on neurological disorders.

The Pandemic and All-Hazards Preparedness Reauthorization Act of 2013 (S.242) ensures continued funding and strategic direction for public health emergency preparedness. This bill maintains existing support for pharmaceutical companies, medical device manufacturers, and healthcare service providers involved in national health security.

The Pandemic and All-Hazards Preparedness Reauthorization Act of 2013 (PAHPRA) solidified federal funding and strategic direction for public health emergencies. This act directly benefited pharmaceutical and biotechnology companies involved in vaccine and therapeutic development, ensuring sustained government procurement.

The Immediate Access for the Terminally Ill Act accelerates patient access to experimental treatments, directly benefiting pharmaceutical and biotechnology companies developing late-stage therapies. This bill expands the market for investigational drugs, increasing revenue potential for companies with promising pipelines.

The Immediate Access for the Terminally Ill Act accelerates patient access to experimental drugs, increasing revenue opportunities for pharmaceutical companies with late-stage clinical pipelines. This bill directly expands the market for investigational therapies by reducing regulatory hurdles.

The 'Skinny Labels, Big Savings Act' directly targets brand-name pharmaceutical companies by limiting their ability to block generic competition. This legislation will reduce drug prices and significantly decrease revenue for innovator drug manufacturers, while benefiting generic drug producers.